title: Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation.
abstract: BACKGROUND
  N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a diagnostic biomarker for patients with congestive heart failure (CHF). However, the clinical significance of measurements of NT-proBNP levels in patients with coronary artery disease (CAD) who have undergone drug-eluting stent (DES) implantation has not been fully elucidated.
  
  
  RESULTS
  We recruited 280 patients with documented CAD who were scheduled for elective coronary intervention and also age- and gender-matched 140 healthy subjects. Subjects with acute coronary syndrome, ongoing CHF, and stage IV or V chronic kidney disease were excluded. We measured the plasma NT-proBNP levels and followed the CAD patients who have undergone DES implantation for up to 62 months until occurrence of major adverse cardiovascular events (MACE). Plasma NT-proBNP levels were significantly higher in CAD patients compared to control subjects (p<0.0001). In the CAD group, 25 patients developed MACE and the NT-proBNP levels in the MACE group were significantly higher compared to that in the non-MACE group (p=0.005). After adjusting for the confounding factors, high NT-proBNP levels were observed to be independent factors for CAD (p<0.0001) and MACE (p=0.021).
  
  
  CONCLUSIONS
  These results demonstrated that the measurements of NT-proBNP levels may be useful in identifying high-risk subjects among CAD patients who have undergone elective DES implantation.
authors.affiliation: Department of Cardiovascular Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Masaki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Shimada
authors.forename: Takahiko
authors.initials: T
authors.lastname: Kojima
authors.forename: Katsumi
authors.initials: K
authors.lastname: Miyauchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Inoue
authors.forename: Takashi
authors.initials: T
authors.lastname: Kiyanagi
authors.forename: Makoto
authors.initials: M
authors.lastname: Hiki
authors.forename: Kosuke
authors.initials: K
authors.lastname: Fukao
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Hirose
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Ohsaka
authors.forename: Atsumi
authors.initials: A
authors.lastname: Kume
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Ohmura
authors.forename: Akimichi
authors.initials: A
authors.lastname: Ohsaka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Daida
mesh_terms: D015415:Biomarkers / Q000097:blood; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain